The Personalized Cancer Vaccines Market is characterized by a broad range of technologies and applications designed to support individualized cancer treatment. The market is projected to expand from USD 5.2 billion in 2025 to USD 25 billion by 2035, with a CAGR of 17.1%.

By technology, the market includes dendritic cell vaccines, peptide vaccines, viral vector vaccines, and DNA vaccines. These technologies use different approaches to stimulate immune responses against cancer-specific targets. DNA vaccines and dendritic cell-based approaches are receiving significant research attention because of their potential applications in personalized oncology.

By therapeutic area, breast cancer, lung cancer, prostate cancer, and melanoma represent important segments. The increasing incidence of these cancers and demand for targeted treatment options are contributing to market development.

Administration routes include intramuscular, intravenous, and subcutaneous delivery. Hospitals, cancer research institutes, and private clinics represent key end users.

The competitive landscape includes major pharmaceutical and biotechnology companies such as Merck, BioNTech, Moderna, Bristol Myers Squibb, CureVac, Genentech, Agenus, Immatics, Eisai, and other industry participants.

North America is anticipated to remain a major market, while Asia-Pacific is expected to demonstrate strong growth because of rising healthcare investments and increasing adoption of advanced cancer therapies.

Research collaborations, technological innovation, clinical development, and strategic partnerships are expected to shape the competitive environment.